CA2321215A1 - Hybrid adenovirus-aav virus and method of use thereof - Google Patents

Hybrid adenovirus-aav virus and method of use thereof Download PDF

Info

Publication number
CA2321215A1
CA2321215A1 CA002321215A CA2321215A CA2321215A1 CA 2321215 A1 CA2321215 A1 CA 2321215A1 CA 002321215 A CA002321215 A CA 002321215A CA 2321215 A CA2321215 A CA 2321215A CA 2321215 A1 CA2321215 A1 CA 2321215A1
Authority
CA
Canada
Prior art keywords
hybrid
aav
transgene
host cell
aav virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002321215A
Other languages
French (fr)
Other versions
CA2321215C (en
Inventor
James M. Wilson
William M. Kelley
Krishna J. Fisher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
The Trustees Of The University Of Pennsylvania
James M. Wilson
William M. Kelley
Krishna J. Fisher
Trustees Of The University Of Pennsylvania (The)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/331,384 external-priority patent/US5856152A/en
Application filed by The Trustees Of The University Of Pennsylvania, James M. Wilson, William M. Kelley, Krishna J. Fisher, Trustees Of The University Of Pennsylvania (The) filed Critical The Trustees Of The University Of Pennsylvania
Priority claimed from CA 2203808 external-priority patent/CA2203808C/en
Publication of CA2321215A1 publication Critical patent/CA2321215A1/en
Application granted granted Critical
Publication of CA2321215C publication Critical patent/CA2321215C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Abstract

The present invention provides a hybrid vector construct which comprises a portion of an adenovirus, 5" and 3" ITR sequences from an AAV, and a selected transgene. Also provided is a hybrid virus linked via a polycation conjugate to an AAV rep gene to form a single particle. These trans-infection particles are characterized by higher titer transgene delivery to a host cell and the ability to stably integrate the transgene into the host cell chromosome. Also disclosed is the use of the hybrid vectors and viruses to produce large quantities of recombinant AAV.
CA002321215A 1994-10-28 1995-10-27 Hybrid adenovirus-aav virus and method of use thereof Expired - Lifetime CA2321215C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/331,384 US5856152A (en) 1994-10-28 1994-10-28 Hybrid adenovirus-AAV vector and methods of use therefor
US08/331,384 1994-10-28
CA 2203808 CA2203808C (en) 1994-10-28 1995-10-27 Hybrid adenovirus-aav virus and method of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA 2203808 Division CA2203808C (en) 1994-10-28 1995-10-27 Hybrid adenovirus-aav virus and method of use thereof

Publications (2)

Publication Number Publication Date
CA2321215A1 true CA2321215A1 (en) 1996-05-09
CA2321215C CA2321215C (en) 2009-04-14

Family

ID=25679278

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002321215A Expired - Lifetime CA2321215C (en) 1994-10-28 1995-10-27 Hybrid adenovirus-aav virus and method of use thereof

Country Status (1)

Country Link
CA (1) CA2321215C (en)

Also Published As

Publication number Publication date
CA2321215C (en) 2009-04-14

Similar Documents

Publication Publication Date Title
WO1996013598A3 (en) Hybrid adenovirus-aav virus and method of use thereof
WO2000028061A3 (en) Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
WO1999011764A3 (en) Methods for generating high titer helper-free preparations of recombinant aav vectors
CA2192215A1 (en) Recombinant aav genome encoding immunodeficiency virus protein
EP0793713A4 (en) Adeno-associated derived vector systems for gene delivery and integration into target cells
CA2236968A1 (en) Accessory functions for use in recombinant aav virion production
CA2161962A1 (en) Adenovirus vectors for gene therapy
WO2003052052A3 (en) Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
EP1453547A4 (en) Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
WO2003092594A3 (en) Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
CA2303477A1 (en) Chimaeric adenoviruses
CA2187626A1 (en) Aav-mediated delivery of dna to cells of the nervous system
CA2225278A1 (en) Recombinant mva virus, and the use thereof
EP1707631A3 (en) An improved method for the production and purification of adenoviral vectors
CA2366861A1 (en) Compositions and methods for helper-free production of recombinant adeno-associated viruses
JP2002538770A5 (en)
WO1998011244A3 (en) AAV4 vector and uses thereof
AU681705B2 (en) Endosomolytically active particles
WO2000003030A3 (en) Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
AU6704496A (en) Helper viruses for the preparation of recombinant viral vectors
CA2421442A1 (en) Host cells for packing a recombinant adeno-associated virus (raav), method for the production and use thereof
WO2001036623A3 (en) Ecdysone-inducible adeno-associated virus expression vectors
CA2047290A1 (en) Recombinant marek's disease virus
NZ334827A (en) High-capacity adenoviral vectors suitable for adenoviral-based gene therapy
WO1998055639A3 (en) Recombinant adenoviral vectors comprising a splicing sequence

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20151027